Abstract: The present application relates to the use of a phthalazinedione in the prevention or treatment of sequelae of a SARS-CoV-2 infection. Pharmaceutical compositions, combinations, advantageous formulation techniques and a method of treatment are disclosed.
Type:
Application
Filed:
December 1, 2021
Publication date:
March 7, 2024
Applicant:
METRIOPHARM AG
Inventors:
Wolfgang BRYSCH, Astrid KAISER, Petra SCHULZ, Sara SCHUMANN, Jörg WEGERER
Abstract: The present invention relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione or its pharmaceutically acceptable N salts in the inhalatory treatment of inflammatory pulmonary diseases. The invention in particular relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione sodium salt for said purposes. Advantageous features of an aerosol containing 5-amino-2,3-dihydro-1,4-phthalazinedione or its pharmaceutically acceptable salts and a method for producing said aerosol are disclosed. The present invention further relates to a kit for inhalatory treatment of inflammatory pulmonary diseases.
Type:
Application
Filed:
January 29, 2021
Publication date:
March 2, 2023
Applicant:
MetrioPharm AG
Inventors:
Wolfgang Brysch, Astrid Kaiser, Petra Schulz, Sara Schumann, Jörg von Wegerer
Abstract: A new method for producing a crystalline form of 5-amino-2,3-dihydro-1,4-phthalazinedione (luminol) is provided. Advantageous uses for this crystalline form as a detecting agent or as an agent for forensic purposes are disclosed, as well a pharmaceutical composition containing said crystalline form.
Type:
Grant
Filed:
February 15, 2017
Date of Patent:
December 21, 2021
Assignee:
MetrioPharm AG
Inventors:
Thomas Martin, Josef Breu, Juliane Fleissner, Wolfgang Brysch, Jörg Von Wegerer
Abstract: A new crystalline form of 5-amino-2,3-dihydro-1,4-phthalazinedione (luminol) is provided. Advantageous uses for this crystalline form as a detecting agent or as an agent for forensic purposes are disclosed, as well a pharmaceutical composition containing said crystalline form.
Type:
Grant
Filed:
February 15, 2017
Date of Patent:
September 7, 2021
Assignee:
METRIOPHARM AG
Inventors:
Thomas Martin, Josef Breu, Juliane Fleissner, Wolfgang Brysch, Jörg Von Wegerer
Abstract: The invention relates to 5-amino-2,3-dihydro-1,4-phthalazinedione or related compounds, compositions or combinations thereof, for use in the treatment of chronic progressive multiple sclerosis, in particular primary and secondary progressive multiple sclerosis. The invention in particular relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione sodium salt for said purposes.
Type:
Grant
Filed:
November 6, 2017
Date of Patent:
May 18, 2021
Assignee:
Metriopharm AG
Inventors:
Wolfgang Brysch, Astrid Kaiser, Claudia Van Laak, Beate Ludescher, Maliha Shah, Jörg Von Wegerer
Abstract: The present invention relates to a method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione or salts thereof, to the solubilisate produced by this method and respective uses in pharmaceutical dosage forms. A phosphatidylcholine-based solubilization method is disclosed.
Abstract: A new crystalline form of 5-amino-2,3-dihydro-1,4-phthalazinedione (luminol) is provided. Advantageous uses for this crystalline form as a detecting agent or as an agent for forensic purposes are disclosed, as well a pharmaceutical composition containing said crystalline form.
Type:
Application
Filed:
February 15, 2017
Publication date:
November 26, 2020
Applicant:
MetrioPharm AG
Inventors:
Thomas MARTIN, Josef BREU, Juliane FLEISSNER, Wolfgang BRYSCH, Jörg von WEGERER
Abstract: A new method for producing a crystalline form of 5-amino-2,3-dihydro-1,4-phthalazinedione (luminol) is provided. Advantageous uses for this crystalline form as a detecting agent or as an agent for forensic purposes are disclosed, as well a pharmaceutical composition containing said crystalline form.
Type:
Application
Filed:
February 15, 2017
Publication date:
November 26, 2020
Applicant:
MetrioPharm AG
Inventors:
Thomas MARTIN, Josef BREU, Juliane FLEISSNER, Wolfgang BRYSCH, Jörg von WEGERER
Abstract: The invention relates to the provision of a new crystalline form for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium, the use of this form for medical purposes, methods for producing the crystalline form according to the invention, as well as pharmaceutical preparations comprising said form.
Type:
Grant
Filed:
December 18, 2015
Date of Patent:
April 16, 2019
Assignee:
Metriopharm AG
Inventors:
Thomas Martin, Josef Breu, Wolfgang Brysch, David Kosel, Beate Ludescher, Michael Niedermaier, Jörg Von Wegerer
Abstract: The invention relates to the provision of a new crystalline form for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium, the use of this form for medical purposes, methods for producing the crystalline form according to the invention, as well as pharmaceutical preparations comprising said form.
Type:
Application
Filed:
December 18, 2015
Publication date:
December 28, 2017
Applicant:
METRIOPHARM AG
Inventors:
Thomas Martin, Josef Breu, Wolfgang Brysch, David Kosel, Beate Ludescher, Michael Niedermaier, Jörg Von Wegerer
Abstract: The invention relates to the provision of two novel crystalline forms I and II for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt. Surprisingly, it was discovered that form I and form II have differing immunological effects. This advantageous property is useful for immunospecific applications. In addition, both forms have advantageous physicochemical properties, which are useful in the production, further processing and/or use of a pharmaceutical preparation of form I or form II or a mixture of both.
Type:
Grant
Filed:
April 8, 2014
Date of Patent:
July 14, 2015
Assignee:
MetrioPharm AG
Inventors:
Josef Breu, Wolfgang Brysch, Astrid Kaiser, Beate Ludescher, Gerrit Maass, Thomas Martin, Wolfgang Milius, Michael Niedermaier
Abstract: The invention relates to the provision of two novel crystalline forms I and II for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt. Surprisingly, it was discovered that form I and form II have differing immunological effects. This advantageous property is useful for immunospecific applications. In addition, both forms have advantageous physicochemical properties, which are useful in the production, further processing and/or use of a pharmaceutical preparation of form I or form II or a mixture of both.
Type:
Application
Filed:
April 8, 2014
Publication date:
October 9, 2014
Applicant:
METRIOPHARM AG
Inventors:
Josef BREU, Wolfgang BRYSCH, Astrid KAISER, Beate LUDESCHER, Gerrit MAASS, Thomas MARTIN, Wolfgang MILIUS, Michael NIEDERMAIER
Abstract: The invention relates to the provision of two novel crystalline forms I and II for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt. Surprisingly, it was discovered that form I and form II have differing immunological effects. This advantageous property is useful for immunospecific applications. In addition, both forms have advantageous physicochemical properties, which are useful in the production, further processing and/or use of a pharmaceutical preparation of form I or form II or a mixture of both.
Type:
Grant
Filed:
March 1, 2011
Date of Patent:
July 8, 2014
Assignee:
MetrioPharm AG
Inventors:
Josef Breu, Wolfgang Brysch, Astrid Kaiser, Beate Ludescher, Gerrit Maass, Thomas Martin, Wolfgang Milius, Michael Niedermaier
Abstract: The invention relates to the provision of two novel crystalline forms I and II for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt. Surprisingly, it was discovered that form I and form II have differing immunological effects. This advantageous property is useful for immunospecific applications. In addition, both forms have advantageous physicochemical properties, which are useful in the production, further processing and/or use of a pharmaceutical preparation of form I or form II or a mixture of both.
Type:
Application
Filed:
March 1, 2011
Publication date:
December 27, 2012
Applicant:
Metriopharm AG
Inventors:
Josef Breu, Wolfgang Brysch, Astrid Kaiser, Beate Ludescher, Gerrit Maass, Thomas Martin, Wolfgang Milius, Michael Niedermaier